Fractyl Health, Inc. Common Stock (GUTS) NASDAQ
0.92
+0.1042(+12.75%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.92
+0.1042(+12.75%)
Currency In USD
| Previous Close | 0.82 |
| Open | 0.84 |
| Day High | 0.92 |
| Day Low | 0.8 |
| 52-Week High | 3.03 |
| 52-Week Low | 0.38 |
| Volume | 1.6M |
| Average Volume | 2.33M |
| Market Cap | 66.51M |
| PE | -0.7 |
| EPS | -1.31 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 1.12 |
| Change | 0.1 |
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data readout BURLINGTON, Mass., Fe
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
GlobeNewswire Inc.
Jan 29, 2026 12:00 PM GMT
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T